The Worldwide Dry Eye Syndrome Treatment Industry is Expected to Reach $6.5 Billion by 2028
16 Jan 2023
Phase 3
DUBLIN, Jan. 16, 2023 /PRNewswire/ -- The "Global Dry Eye Syndrome Treatment Market Size, Share & Industry Trends Analysis Report by Type, Drug, Dosage, Distribution Channel, Sales Channel, Product, Regional Outlook and Forecast, 2022-2028" report has been added to
ResearchAndMarkets.com's offering.
The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
For clear eyesight, the tear film is crucial. Three layers comprise the tear film: an oily layer, a watery layer, and a mucus layer with each layer having a specific function. The exterior of the tear film is the oily layer. It smoothens the tear's surface and slows down the rate of drying.
The meibomian glands in the eye produce this layer. The center of the tear film is the watery layer. The majority of what is perceived as tears is made up of them. By removing foreign objects from the eye, this layer cleanses the eye. The lacrimal glands present in eyelids produce this layer.
The innermost layer of the film is called the mucus layer. This aids in distributing the watery layer and maintaining the eye's moisture.
Tears would not adhere to the eye without mucus, which is produced by the conjunctiva. This is the transparent tissue that lines the interior of the eyelids and the surface of the eye. Normal tear production keeps eyes moist all the time. The eyes produce a lot of tears when they are inflamed or when someone cries.
COVID-19 Impact Analysis
Due to fewer ophthalmologist appointments, the COVID-19 pandemic had a negative effect on the dry eye syndrome treatment market in the initial stages of the pandemic. But as immediately as the eye care businesses started, the market started to recover.
Market Growth Factors
Development of promising drugs to manage Dry Eye Diseases
In various age categories, the estimated concentration ranges from roughly 5% to over 35%. Dry eye (DE) is usually overlooked despite being very common. Dry Eye is a significant burden on the public healthcare system because of its detrimental effects on patients' visual function and life quality.
Therefore, efforts to improve diagnostic procedures and develop suitable DE treatments are merited. Reproxalap (Alderya Therapeutics), tivanisiran (Sylentis), tanfanercept (HanAll BioPharma), timbetasin (Regenerx), loteprednol etabonate (Kala Pharma), and NOV03 (Bausch + Lomb) are few of the medications that were recently investigated in Phase 3 trials for the treatment of dry eyes. As these development continue to proceed, they aid in the expansion of the dry eye syndrome treatment market.
Availability of different procedures and medicines to suit the majority
Burning, Itching, irritation, eye tiredness, and ocular inflammation are among the prominent symptoms of DED, which can vary from mild to serious and can potentially cause impairment to the cornea, conjunctiva, and even loss of eyesight.
As a result, the treatment must be customized to each patient by focusing on the distinct mechanisms linked to their condition, depending on the various presentations and pathophysiology. The tailoring of the medical procedure allows patients to think about the pros and cons before going for treatment.
This provides satisfaction and additional comfort to patients which tremendously helps in the success of treatment. This, in turn, will bolster the growth of the dry eye syndrome treatment market.
Market Restraining Factors
Drug approval takes a longer time
Drug approval entails several expensive regulatory approvals and research phases. About four steps of clinical trials are involved in the drug approval process, as well as different stages of screening by regulatory agencies like the FDA. Because clinical trial phases need significant investments, the costs of unsuccessful trials are also large.
For instance, a Forbes article estimates that a drug manufacturer spends roughly $350 million on each treatment before it is introduced to the market. This demonstrates significant drug approval costs that are expected to have an impact on the market for dry eye medications. Additionally, long waiting times also add up to lost money for these manufacturers, and as such hampers the growth of the dry eye syndrome treatment market.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Global Dry Eye Syndrome Treatment Market by Type
4.1 Global Evaporative Dry Eye Syndrome Market by Region
4.2 Global Aqueous Deficient Dry Eye Syndrome Market by Region
Chapter 5. Global Dry Eye Syndrome Treatment Market by Drug
5.1 Global Restasis Market by Region
5.2 Global Xiidra Market by Region
5.3 Global Cequa Market by Region
5.4 Global Eysuvis Market by Region
5.5 Global Tyrvaya & Others Market by Region
Chapter 6. Global Dry Eye Syndrome Treatment Market by Dosage
6.1 Global Eye drops Market by Region
6.2 Global Gels Market by Region
6.3 Global Capsules & Tablets Market by Region
6.4 Global Eye Solutions Market by Region
6.5 Global Ointments Market by Region
Chapter 7. Global Dry Eye Syndrome Treatment Market by Distribution Channel
7.1 Global Retail Pharmacy Market by Region
7.2 Global Hospital Pharmacy Market by Region
7.3 Global Online Pharmacy Market by Region
Chapter 8. Global Dry Eye Syndrome Treatment Market by Sales Channel
8.1 Global OTC Market by Region
8.2 Global Prescription Market by Region
Chapter 9. Global Dry Eye Syndrome Treatment Market by Product
9.1 Global Cyclosporine Market by Region
9.2 Global Topical Corticosteroids Market by Region
9.3 Global Artificial Tears Market by Region
9.4 Global Punctal Plugs Market by Region
9.5 Global Oral Omega Supplements Market by Region
9.6 Global Others Market by Region
Chapter 10. Global Dry Eye Syndrome Treatment Market by Region
Chapter 11. Company Profiles
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Segmental &Regional Analysis
11.1.4 Research & Development Expenses
11.1.5 Recent strategies and developments:
11.1.5.1 Product Launches and Product Expansions:
11.1.5.2 Approvals and Trials:
11.1.6 SWOT Analysis
11.2 AbbVie, Inc.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Partnerships, Collaborations, and Agreements:
11.2.5.2 Product Launches and Product Expansions:
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental and Regional Analysis
11.3.4 Research & Development Expense
11.3.5 Recent strategies and developments:
11.3.5.1 Partnerships, Collaborations, and Agreements:
11.3.5.2 Product Launches and Product Expansions:
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Segmental and Regional Analysis
11.4.4 Research & Development Expense
11.4.5 Recent strategies and developments:
11.4.5.1 Acquisition and Mergers:
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Regional Analysis
11.5.4 Research & Development Expenses
11.5.5 Recent strategies and developments:
11.5.5.1 Product Launches and Product Expansions:
11.5.5.2 Approvals and Trials:
11.6 AFT Pharmaceuticals
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Segmental Analysis
11.6.4 Research & Development Expenses
11.6.5 Recent strategies and developments:
11.6.5.1 Product Launches and Product Expansions:
11.7.1 Company Overview
11.7.2 Financial Analysis
11.7.3 Regional Analysis
11.7.4 Research & Development Expenses
11.7.5 Recent strategies and developments:
11.7.5.1 Acquisition and Mergers:
11.7.5.2 Approvals and Trials:
11.8.1 Company Overview
11.8.2 Financial Analysis
11.8.3 Research & Development Expenses
11.8.4 Recent strategies and developments:
11.8.4.1 Partnerships, Collaborations, and Agreements:
11.8.4.2 Approvals and Trials:
11.9 OASIS Medical, Inc.
11.9.1 Company Overview
11.9.2 Recent strategies and developments:
11.9.2.1 Product Launches and Product Expansions:
11.10.1 Company Overview
For more information about this report visit https://www.researchandmarkets.com/r/j3p0ey
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.